ozekibart Updated Nov 13
The next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.
- Registrational trial showed ozekibart reduced the risk of disease progression or death by 52% vs placebo, a clinically meaningful result in a setting with no approved therapies.
- BLA was accepted by FDA with no filing review issues identified, and a PDUFA date is set for April14,2027 -- a clear binary catalyst within ~5 months.
- If approved, ozekibart would be the first and only FDA-approved systemic treatment for unresectable or metastatic conventional chondrosarcoma, a clear orphan-drug market.
- Inhibrx has $199.5M cash vs $275M in debt and a $38.7M quarterly burn, requiring the newly filed $150M ATM (filed Nov13,2026) that dilutes existing shareholders.
- Short interest is ~23% of shares outstanding as of October30,2026, with 10 days to cover -- a heavy bearish bet against approval or commercial success.
- No FDA-approved systemic therapy currently exists for chondrosarcoma, and the FDA could still issue a Complete Response Letter despite positive data.